文献速递眼底病与葡萄膜炎

吸烟与新生血管性年龄相关性黄斑变性12个月治疗结局的关系

Smoking and treatment outcomes of neovascular age-related macular degeneration over 12 months.
PubMed 文献 · Br J Ophthalmol · 2019-09-26

该研究纳入547例新生血管性年龄相关性黄斑变性(nAMD)患者,其中490例完成12个月随访,评估吸烟与发病年龄、视力、中心黄斑厚度及积液的关系。多变量调整后,当前吸烟者发病年龄较从未吸烟者平均年轻5.5岁,较过去吸烟者年轻4.4岁;当前吸烟者基线中心黄斑厚度显著高于过去吸烟者;当前吸烟者较从未吸烟者12个月时存在视网膜下积液的比值比为1.99。吸烟状态与12个月视力无显著关联。

要点

  • 当前吸烟者nAMD发病年龄较从未吸烟者平均年轻5.5岁,较过去吸烟者年轻4.4岁。
  • 当前吸烟者基线中心黄斑厚度显著高于过去吸烟者(259.2 µm vs 231.9 µm)。
  • 当前吸烟者较从未吸烟者12个月时存在视网膜下积液的比值比为1.99(95% CI 1.09至3.67)。

核心结论

  • 当前吸烟与nAMD发病年龄更年轻、平均中心黄斑厚度更高及视网膜下积液存在比值更高相关。
  • 这些发现提示戒烟可能对正在接受治疗的nAMD患者有益。

研究设计与样本

  • 2012至2015年间从一家三级眼科诊所招募547例nAMD患者,其中490例在12个月后完成随访。
  • nAMD临床诊断由视网膜专科医生确认,吸烟状态依据自我报告史分为从未、过去或当前吸烟。
  • 发病年龄定义为任一眼首次记录nAMD诊断的日期或首次抗血管内皮生长因子注射的日期。
  • 中心黄斑厚度和积液存在情况通过谱域光学相干断层扫描图像记录,视力记录为3米处阅读的字母数。

主要发现

  • 多变量调整后,当前吸烟者nAMD发病年龄较从未吸烟者平均年轻5.5岁(p<0.0001),较过去吸烟者平均年轻4.4岁(p=0.0008)。
  • 基线时,当前吸烟者调整后平均中心黄斑厚度显著高于过去吸烟者(259.2 µm vs 231.9 µm,p=0.04)。
  • 当前吸烟者较从未吸烟者12个月随访时存在视网膜下积液的比值比为1.99(95% CI 1.09至3.67)。
  • 吸烟状态与12个月视力无显著关联。

临床怎么用

  • 原文结论指出这些发现提示戒烟可能对正在接受治疗的nAMD患者有益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To assess the association of smoking with age of onset of neovascular age-related macular degeneration (nAMD), visual acuity (VA), central macular thickness (CMT) and the presence of fluid in patients with nAMD. METHODS: 547 patients with nAMD were recruited from a tertiary eye clinic during 2012-2015; of these, 490 patients were followed up 12 months later. Clinical diagnosis of nAMD was confirmed by a retinal specialist. Smoking was determined from self-reported history as never, past or current. Age of onset was defined as date of first recorded diagnosis of nAMD in either eye or date of first anti-vascular endothelial growth factor injection. CMT and presence of fluid were recorded from spectral-domain optical coherence tomography images. VA was recorded as number of letters read at 3 m. RESULTS: After multivariable adjustment, current smokers developed nAMD at an average 5.5 years younger age than never smokers and 4.4 years younger age than past smokers (p<0.0001 and p=0.0008, respectively). At baseline, adjusted mean CMT was significantly higher in current compared with past smokers (259.2 µm vs 231.9 µm, respectively, p=0.04). Current smokers versus never smokers had greater odds of presence of subretinal fluid at 12-month follow-up: multivariable-adjusted OR 1.99 (95% CI 1.09 to 3.67). Smoking status was not significantly associated with VA over 12 months. CONCLUSIONS: Current smoking was associated with a younger age of nAMD onset and key treatment outcomes such as higher mean CMT and greater odds of subretinal fluid presence. These findings suggest that smoking cessation may benefit patients being treated for nAMD.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Detaram HD, Joachim N, Liew G, et al. Smoking and treatment outcomes of neovascular age-related macular degeneration over 12 months. Br J Ophthalmol. 2019. PMID: 31558491. doi:10.1136/bjophthalmol-2019-314849

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。